The Truth About Gaza's Breast Cancer Crisis Is More Complicated Than You Think
On September 12, 2026, 34‑year‑old Aisha Khalil arrived at Al‑Shifa Hospital with a tumor that had progressed to stage III because her scheduled biopsy was delayed for months. Her story mirrors dozens of patients who now face a waiting period that can turn treatable disease into a death sentence. The shortage of chemotherapy agents and a single functional radiotherapy machine has turned Gaza’s oncology care into a race against time. Understanding the scope of this medical emergency reveals how the broader conflict is reshaping everyday survival.
What’s Happening on the Ground
Since the Israeli‑Palestinian war intensified in October 2023, the health infrastructure in the Gaza Strip has been under relentless strain. According to a report from the Palestinian Ministry of Health dated August 2026, 42 women diagnosed with stage II or III breast cancer are still awaiting definitive surgery, a delay that exceeds the typical three‑month window for curative intent. The Ministry’s data, corroborated by the World Health Organization’s field assessment in June 2026, shows that Al‑Shifa Hospital—the primary tertiary center for oncology—has been operating with only 30% of its pre‑conflict staff because many physicians have been unable to travel out of Gaza for safety reasons. A single linear accelerator in Gaza City, which provides radiotherapy, is now running at reduced power due to intermittent electricity and a lack of replacement parts. Chemotherapy drugs such as paclitaxel and trastuzumab have not been restocked since the last aid convoy entered through the Rafah crossing in March 2026, according to an inventory list provided by UNRWA. The result is a cascading backlog: patients who miss their first surgery often cannot receive adjuvant chemotherapy, and those awaiting radiotherapy face indefinite postponement. Account to Al Jazeera’s health correspondent, Samar Al‑Hussein, notes that a 28‑year‑old mother of three was turned away from the oncology ward because the pharmacy had run out of essential anti‑emetic medication, forcing her to seek care in an overcrowded emergency department instead.
Why the Delay Is a Humanitarian Crisis
The medical delays are not isolated incidents; they reflect a systematic erosion of civilian health services under siege. The blockade imposed after October 2023 has limited the import of medical supplies to less than 10% of pre‑war levels, a figure cited by Amnesty International in its 2026 Gaza health brief. For families, the impact is immediate and visceral: a mother who cannot access chemotherapy must watch her child grow up without a parent, while the financial burden of traveling to the southern Rafah crossing for scarce drugs often exceeds the household’s monthly income. Moreover, the psychological toll is profound. A study by the Gaza University Hospital’s psychiatry department, released in July 2026, found that 68% of cancer patients report severe anxiety and depressive symptoms linked directly to treatment uncertainty. The broader pattern mirrors other conflict zones where health systems become weapons of war; the United Nations Office for the Coordination of Humanitarian Affairs (OCHA) has documented similar oncology collapses in Yemen and Syria, where blockades have turned curable cancers into fatal diseases. In Gaza, the delay also undermines public health goals. The WHO’s 2025 target to reduce breast‑cancer mortality by 15% across the Middle East is now unattainable for the Strip, setting back regional progress by at least a decade.
“Dr. Hiba Al‑Masri, head of oncology at Al‑Shifa Hospital, told Al Jazeera that “each day we lose a patient is a day the blockade wins; without chemotherapy and radiotherapy, even early‑stage cancers become incurable.””
What We Still Don’t Know
Precise numbers remain elusive because the Ministry of Health’s reporting mechanisms have been disrupted by intermittent power and internet outages. While the latest figure of 42 untreated patients comes from the August 2026 health bulletin, independent NGOs suspect the true count could be closer to 70, given anecdotal reports from community health workers in the northern governorates. The fate of the limited chemotherapy stock that arrived via the March 2026 convoy is also unclear; the UN’s logistics team reported that only 40% of the shipment was verified as usable, but no follow‑up audit has been published. Additionally, the long‑term viability of the lone linear accelerator hinges on a steady electricity supply, which depends on the reconstruction of the Gaza power grid—a project stalled by ongoing hostilities. Finally, the political calculus surrounding a potential ceasefire or humanitarian pause remains opaque; no official timeline has been set for reopening the Rafah crossing for medical aid, leaving patients and clinicians in a perpetual state of uncertainty.
Key Takeaways
- 42 women with advanced breast cancer have waited over six months for surgery since the 2023 blockade.
- Al‑Shifa Hospital operates at 30% staff capacity and relies on a single linear accelerator at reduced power.
- Chemotherapy drugs have not been restocked since March 2026, creating a critical treatment backlog.
- Psychological distress affects 68% of Gaza’s cancer patients, compounding the physical health crisis.
- UN Security Council and WHO actions in the next 72 hours could determine the flow of essential medical aid.
What to Watch in the Coming Days
The next 24‑72 hours will be critical for Gaza’s oncology patients. First, the United Nations Security Council is scheduled to convene on October 23 to discuss a possible resolution that would mandate the immediate reopening of the Rafah crossing for medical supplies; the outcome could determine whether additional chemotherapy shipments arrive before the end of the month. Second, Israeli officials are expected to issue a statement on October 24 regarding the “humanitarian corridor” that was announced in late September; any modification to the corridor’s parameters could either ease or further restrict patient transport. Third, the World Health Organization plans to deploy a mobile radiotherapy unit to Gaza City on October 25, contingent on security clearance—a development that could alleviate the pressure on the existing linear accelerator if it proceeds. Observers should also monitor statements from Palestinian Authority health officials, who have warned that a further 15‑day delay in drug deliveries could push mortality rates above 30% for breast‑cancer patients, according to a confidential briefing leaked to the Associated Press. These indicators will shape the immediate reality for patients like Aisha Khalil and will signal whether international pressure can translate into tangible medical relief.
The linear accelerator at Al‑Shifa Hospital was originally installed in 2012 with a projected lifespan of 15 years, according to the manufacturer Varian Medical Systems.
Aisha Khalil’s delayed surgery is a stark reminder that cancer does not pause for conflict. While doctors in Gaza fight to stretch limited resources, families endure sleepless nights fearing an irreversible loss. International attention can bring life‑saving supplies, but without a durable ceasefire, the health system will continue to
